EpCAM-specific monoclonal antibodies (mAbs) have been used in treating human colorectal cancer since 1900, with a 30% increase in five-year survival and a 27% reduction in recurrence rates within 7 years of treatment (Hoshino et al., 2015). Here, EPCAM is linked to colorectal cancer.